KRAS2–4/NRAS2–4/BRAF15 mut were often detected at <5% AF (13.3%), all involving MCRC patients harbouring >2 KRAS and/or NRAS mut and prevalently involving atypical BRAF mutations, different from that typically reported (codon 600) in CRC [14]. This evidence concerns the gene KRAS and colorectal carcinoma.